Pfizer To Sell Paxlovid In China As Covid Cases Surge
Date
12/14/2022 11:29:12 PM
(MENAFN- The Peninsula) Bloomberg
Beijing: Pfizer Inc. clinched an agreement to sell its antiviral medication Paxlovid in China through a state-owned company, making the drug available to battle surging COVID-19 cases.
China Meheco Group Co. signed an agreement Wednesday with Pfizer to import and distribute Paxlovid on the mainland, the company said in a filing with the Shanghai Stocks Exchange. The agreement is effective immediately. Terms weren't disclosed.
With COVID infections surging in Beijing, Paxlovid will help the government contain the outbreak after authorities made an about-face and reversed their strict approach to combating the pandemic.
The agreement follows China's surprise decision in February to clear the coronavirus pill for use. The news site Caixin reported on Tuesday that online Chinese pharmacy 111 Inc. had started presale of Paxlovid for 2,980 yuan ($427) per box. The company later said that media interpretation was 'inaccurate.”
Read Also china says tracking covid cases 'impossible' as infections soar hong kong drops curbs on incoming travellers, scraps covid app china's cyclical recovery to be delayed by new wave of covid-19 cases china tackles medical supply snags, price gouging amid covid fears
It's unclear how quickly Paxlovid will be widely available on the Chinese market. Merck & Co. in September struck a deal with Chinese state-owned drugmaker Sinopharm to import and market its antiviral molnupiravir in the country.
China Meheco said its agreement with Pfizer will expire on November 30, 2023.
MENAFN14122022000063011010ID1105311469
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.